Live Webinar 1: PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape (2021)

March 24, 2021

Complimentary CME Webinar!

Wednesday, March 24, 2021 | 7:00 - 8:00 p.m. EST


PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion. 

Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care. 

The PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape Webinar will be recorded and available in webcast format on AUAUniversity and AUA’s YouTube channel. Additionally, the content will be released as an episode on AUA’s podcast. 


Acknowledgements

This educational series is supported by independent educational grants from:

  • AstraZeneca
  • Merck

 

 

Target Audience

  • Urologist
  • Resident
  • Nurse Practitioner
  • Physician Assistant

Learning Objectives

At the conclusion of  PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape, participants will be able to:

  1. Review recommended criteria for genetic testing of prostate cancer patients, currently available gene panels, and options for testing these men.
  2. Explain the importance of testing for germline mutations and their implication for cascade testing, other personal cancer screening (i.e. male breast cancer), as well as utilizing novel targeted therapies such as PARP inhibitors alone or in combination with alternate modalities.
  3. Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening and surveillance and or management options.

 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
02/02/2021
Course expires: 
03/24/2024
Event starts: 
03/24/2021 - 7:00pm
Event ends: 
03/24/2021 - 8:00pm
Rating: 
0

Times are listed in EDT and are subject to change.

Wednesday, March 24, 2021
7  p.m.Welcome/Introduction & Pre-Test
Segment I
7:10  p.m.Genetic Testing 
Segment II
7:25 p.m.Germline Genetics in Prostate Cancer
Segment III
7:40  p.m.Inherited Syndromes
  
7:55 p.m. Post-Test
  

8 p.m.

Course Adjourns

PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape (2021) will be held virtually on Wednesday, March 24, 2021 at 7:00 - 8:00 p.m. EST.

***Instructions***

  1. Click on the TAKE COURSE button.
  2. Click “Start” under "Live Webinar" in the Course Progress pane.
  3. Click on the link provided to register in advance for this webinar.
  4. After registering, you will receive a confirmation email containing information about joining the webinar. 

 

Education Council Disclosures

PDF iconEducation Council Disclosures

COI Review Work Group Disclosures

PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

Faculty disclosures will be posted here prior to the start of the course.

ACCREDITATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the  program directors  and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence‐based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point‐counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit  equipment  representatives  to  providing  logistics  and  operation  support  only  
  • in  procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off‐label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


AUA Participant Information and Policies

DISCLAIMER:

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

AUDIO, VIDEO AND PHOTOGRAPHIC EQUIPMENT:

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meetings.

REPRODUCTION PERMISSION: 

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

SPECIAL ASSISTANCE/DIETARY NEEDS:

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.

Registration is complimentary.

To register for the webinar:

  1. Click on the TAKE COURSE button.
  2. Click “Start” under "Live Webinar" in the Course Progress pane.
  3. Click on the link provided to register in advance for this webinar.
  4. After registering, you will receive a confirmation email containing information about joining the webinar.